

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and
Waivers under 18 U.S.C. § 208(b)(3) and 21 U.S.C. §355 (n)(4)

Patricia Chesney, M.D.

Committee: Arthritis Drugs Advisory Committee

Meeting Date: November 29, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to new drug application NDA 20-998, supplement 021, trade name, Celebrex (celecoxib), a non-steroidal anti-inflammatory drug (COX-2 inhibitor), manufactured by Searle Ltd. for G.D. Searle LLC, subsidiaries of Pfizer, for the proposed indication of the relief of the signs and symptoms of juvenile rheumatoid arthritis (JRA) in patients two years and older, I am eligible to receive waivers under 18 U.S.C. §208(b)(3) and 21 U.S.C. §355 (n)(4).

Type of Interest	Nature	Magnitude
Stock	Sponsor	Valued from \$25,001 to \$50,000
Stock	Competing Firm	Value less than \$5,001

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waivers are not valid.

_____/S/_____
Signature of SGE

October 24, 2006
Date